Dr. Chakraborty completed his undergraduate (B.Sc) and Masters (M.Sc) degrees in India. He came to the USA for graduate studies at Cold Spring Harbor Laboratory, as a student in the joint program with Stony Brook University and studied the importance of Myc proteolysis in cancer. Following his PhD, he moved to Boston for post-doctoral research and trained under Dr. William Kaelin at the Dana-Farber Cancer Institute/Harvard Medical School. Dr. Chakraborty’s scientific interests include understanding the epigenetic and metabolic perturbations imposed by dysfunctional oxygen-sensing pathways. Dr. Chakraborty’s laboratory at the Cleveland Clinic relies on unbiased screening approaches (e.g., CRISPR/Cas9 screens) to discover novel actionable targets in kidney cancer using both animal and human models.